MAM
Gulf Oil fuels its sales engine with Biresh Singh in the driver’s seat
MUMBAI: It isn’t every day that a seasoned sales general straps in for another ride. But when the road ahead promises a high-speed transformation and a pit crew hungry for growth, the engines are bound to roar. Gulf Oil Lubricants India Ltd. (GOLIL) has shifted gears and brought in a new navigator. Meet Biresh Singh, a 26-year industry vet with a history of turning sluggish sales machines into slick, high-performance units.
Gulf Oil confirmed Singh’s appointment as senior vice president – channel sales. The move is more than a standard hire; it’s a full-throttle play to supercharge Gulf’s B2C growth and dig deep into the digital trenches. Singh, who cut his teeth at Castrol India, knows a thing or two about sales transformation, route-to-market revamps and keeping the channel engine humming.
In his new role, Singh will steer Gulf Oil’s B2C channel expansion strategy, fine-tune route-to-market efficiencies, and plug in digital tools to maximise sales output. And timing? Spot on. The lubricants game is changing, with India’s auto and industrial sectors demanding faster, smarter, cleaner solutions.
Singh brings a decorated toolkit. With a resume stretching over two and a half decades, he’s led business units clocking over Rs 1,000 crore, partnered with top-tier consultants, and built future-ready sales models. From pushing digital enablement to reshaping how field teams hit targets, Singh has done it all—without stalling.
“We are delighted to welcome Biresh Singh to the Gulf Oil family,” said Gulf Oil Lubricants India Ltd MD & CEO Ravi Chawla. “His deep expertise in channel sales, sales transformation, and digital integration aligns perfectly with our vision of strengthening our go-to-market strategy. With our expanding presence across automotive, infrastructure, and industrial sectors aligning with India’s growth story, we have an exceptional opportunity to revolutionise and future-proof our channel sales strategy. As the lubricants industry continues to evolve, Biresh’s leadership will play a crucial role in expanding our channel footprint and driving sustainable business growth.”
Singh, equally revved up, responded, “I am thrilled to join Gulf at such a pivotal moment as the brand reshapes its marketing approach and leads the way in product innovation with customers at the core. I look forward to leveraging my experience in sales transformation, digital adoption, and strategic execution to enhance Gulf Oil’s market reach and deepen customer engagement.”
Armed with a mechanical engineering degree and polished at IIM Ahmedabad’s MDP programme, Singh also boasts credentials from BP’s elite CAPS leadership programme. He isn’t just here to man the wheel—he’s here to redesign the car.
Gulf Oil’s move signals a strategic shift: out with business-as-usual, in with velocity, vision, and some digital grit. With Singh calling the sales plays, GOLIL is banking on smarter routes, stronger connections, and serious market mileage.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
